Voyager Therapeutics Enters into Employment Agreement with New Hires, Impacting Shareholders
LEXINGTON, Mass. Aug.29, 2024 - Voyager Therapeutics, Inc.(Nasdaq: VYGR), a pioneering biotechnology company focused on advancing neurogenetic medicines, has recently signed an employment agreement with a newly hired employee.This agreement includes the granting of a non-qualified stock option and restricted stock units as an inducement to the employee for joining Voyager.The Compensation Committee of Voyager’s Board of Directors approved these inducement awards in compliance with Nasdaq Stock Market Listing Rule 5635(c)(4).The option award was effective on August 28, 2024, and the restricted stock unit award will take effect on October 1, 2024.
This announcement follows previous news from Voyager Therapeutics on their commitment to attracting top talent through inducement grants, which were also granted in accordance with Nasdaq Listing Rule 5635(c)(4).In March 2024, Voyager entered into an employment agreement with Dr.Toby Ferguson, granting him a non-qualified stock option and restricted stock units as part of his inducement to join the company.The option award became effective on March 25, 2024, and the restricted stock unit award was scheduled to become effective on April 1, 2024.
Additionally, in January 2024, Voyager Therapeutics announced the pricing of an underwritten public offering of its common stock.The company offered 7,777,778 shares of its common stock, along with pre-funded warrants to purchase 3,333,333 shares of common stock, at respective public offering prices.The aggregate gross proceeds amounted to approximately $100 million, after deducting underwriting discounts, commissions, and other expenses.The underwriters were also granted a 30-day option to purchase up to an additional 1,666,665 shares of common stock at the public offering price.
These recent developments have had an impact on the shareholders of Voyager Therapeutics Inc.At present, the company has 57.721934 million shares outstanding, with the current price per share set at $6.49.It is evident that the inducement grants provided by Voyager play a significant role in attracting and retaining top talent, ultimately contributing to the company’s growth and success.
In conclusion, Voyager Therapeutics’ commitment to providing inducement grants to new employees highlights their dedication to building a formidable team in the field of neurogenetic medicines.These inducements not only benefit the employees themselves but also have an impact on the company’s shareholders.With the recent employment agreement and the positive response to their public offering earlier this year, Voyager Therapeutics continues to position itself as a leader in the biotechnology industry.
Comments